Actively Recruiting
A Dose-Escalation Study of RO7875913 in Healthy Participants
Led by Genentech, Inc. · Updated on 2026-04-27
40
Participants Needed
1
Research Sites
42 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.
CONDITIONS
Official Title
A Dose-Escalation Study of RO7875913 in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Agree to follow contraception requirements
- Body weight greater than 40 kilograms
- Body mass index between 18 and 30 kg/m2
You will not qualify if you...
- Positive test for hepatitis B surface antigen, hepatitis C virus, or HIV antibody
- History of any cancer
- Major surgery within 28 days before starting study treatment or planned during the study
- Significant metabolic, liver, kidney, lung, heart, blood, digestive, urinary, nerve, or psychiatric disorders
- Known allergy to any part of RO7875913
- Use of investigational biologic therapy within 90 days or 5 drug half-lives before study
- Use of investigational non-biologic therapy within 28 days or 5 drug half-lives before study
- Use of immunosuppressive medication within 28 days or 5 drug half-lives before study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
New Zealand Clinical Research - Christchurch
Christchurch, Canterbury, New Zealand, 8011
Actively Recruiting
Research Team
R
Reference Study ID Number: GO46451 https://forpatients.roche.com/
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here